Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.

To ensure all our e-newsletters get delivered straight to your inbox, we recommend that you add us to your 'safe senders list' - otherwise known as a 'whitelist'. This is a one-time-only task to ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of resilience and curiosity. Now leading the Biopharma product management team at ...